Lexaria Targets Cannabinoids, Tobacco, Hemp, and Pharma Markets with New Subsidiaries
Ryan Allway
November 13th, 2018
Exclusive, News, Top News
The cannabis industry is projected to generation hundreds of billions of dollars of revenue over the coming years, driven by the legalization of medical and recreational cannabis across North America. While many investors are focused on cultivation or dispensary operations, drug delivery technologies may represent an even bigger opportunity. These companies have an opportunity to license their technology and earn high-margin royalties from the industry.
Lexaria Bioscience Corp.’s (OTCQX: LXRP) (CSE: LXX) DehydraTECH drug delivery platform could deliver a three-fold improvement to the bioavailability of cannabinoids, which could be compelling for both medical and recreational companies. In addition, the company believes that the platform has even wider implications across the pharmaceutical and tobacco industries—potentially unlocking billions of dollars in market potential.
Divide and Conquer
Lexaria recently announced the creation of four wholly-owned subsidiaries, each focused on distinct customer bases and business applications. By establishing different subsidiaries, the company will be able to better-focus its research efforts in each area and different financing structures can be used depending on the situation. These different market opportunities could also be spun off much easier down the road.
The four new subsidiaries include:
- Lexaria CanPharm Corp.: Lexaria CanPharm Corp. is a Canadian company focused on providing DehydraTECH technology and other enhancements to the global cannabis industry. Currently, the company is in active discussions related to licensing its technology to companies located in Canada, the U.S., and Europe.
- Lexaria Nicotine Corp.: Lexaria Nicotine Corp. is a U.S. company focused on providing DehydraTECH technology to the global nicotine and tobacco industries. Since 2017, the company has had discussions with several leading tobacco companies around the world and will continue to work towards healthier consumer outcomes.
- Lexaria Hemp Corp.: Lexaria Hemp Corp. is a U.S. company focused on providing DehydraTECH to the rapidly growing hemp-based food and supplements industry. Currently, the company is in discussions with many companies regarding the use of CBD-from-hemp products in the U.S. and Canada.
- Lexaria Pharmaceutical Corp.: Lexaria Pharmaceutical Corp. is a U.S. company focused on licensing DehydraTECH to the large and diverse pharmaceutical sectors, including pain relief, vitamins, PDE5 inhibitors, hormone treatments, CNS conditions, and many other medical conditions.
The company’s growing patent portfolio – already 10 patents granted and over 50 pending – will be divided across these subsidiaries to maximize potential licensing revenue.
DehydraTECH’s Advantage
Lexaria’s proprietary DehydraTECH drug delivery platform is designed to improve the bioavailability of active pharmaceutical ingredients (APIs), as well as make dosing more predictable across patient populations.
By combining APIs with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the taste of underlying ingredients and ensures quick and effective transportation into the bloodstream without degradation in the stomach or liver (e.g. first pass metabolism). Early animal studies have shown that the approach could significantly improve the bioavailability of a wide range of APIs—including cannabinoids.
In a recent clinical study, cannabidiol (CBD) absorption rates were more than three-times higher than the control at the 30-minute mark and continued to significantly surpass control blood level concentrations through the 360-minute measurement. Interestingly, the CBD absorption was even better than GW Pharmaceuticals’ (NASDAQ: GWPH) Mount Sinai study, which used much higher doses of 400 mg and 800 mg to achieve lower blood concentrations.
Looking Ahead
Lexaria Bioscience Corp.’s (OTCQX: LXRP) (CSE: LXX) decision to establish four new subsidiaries will help it capitalize on different market opportunities.
In addition to these developments, the company announced that it will utilize its wholly-owned Poviva Tea Corp. to advance existing ViPova Tea and Coffee consumer brands. Recent legislation in the U.s. supports the possibility of renewed distribution for these brands. These developments could help improve revenue over the intermediate-term.
For more information, visit the company’s website.
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Amercanex was founded with the sole-purpose to ensure a completely transparent, neutral, and non-manipulated marketplace for cannabis industry participants.
BDS Analytics aims to drive the cannabis sector to thrive with well-informed decisions based on factual data. By capturing millions of transactions from dispensary point-of-sale systems we provide actionable insights based on accurate information enabling dispensaries, brands, and growers to sustain their success. Their vision is to be your indispensable source for cannabis industry data […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
